Gilead Lenacapavir cut HIV infections by 96% in trial
A pharmacist holds a vial of lenacapavir, the new HIV prevention injectable drug. Nardus Engelbrecht | AP Gilead‘s twice-yearly shot reduced HIV infections by 96% in a second large study, the company said Thursday. The positive phase three trial data on lenacapavir sets the stage for likely approval by the U.S. Food and Drug Administration … Read more